Jupiter Topco LLC Buys Shares of 23,797 Agios Pharmaceuticals, Inc. $AGIO

Jupiter Topco LLC bought a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 23,797 shares of the biopharmaceutical company’s stock, valued at approximately $883,000.

Several other large investors have also recently made changes to their positions in the business. Sei Investments Co. increased its holdings in shares of Agios Pharmaceuticals by 342.8% during the first quarter. Sei Investments Co. now owns 63,550 shares of the biopharmaceutical company’s stock valued at $2,150,000 after acquiring an additional 49,198 shares in the last quarter. SCS Capital Management LLC purchased a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth about $22,743,000. State of New Jersey Common Pension Fund D bought a new position in Agios Pharmaceuticals in the 4th quarter worth about $1,291,000. GW&K Investment Management LLC boosted its stake in Agios Pharmaceuticals by 41.5% in the 4th quarter. GW&K Investment Management LLC now owns 1,207,301 shares of the biopharmaceutical company’s stock worth $32,863,000 after purchasing an additional 354,359 shares in the last quarter. Finally, Seven Fleet Capital Management LP purchased a new stake in Agios Pharmaceuticals during the 4th quarter valued at about $864,000.

Analyst Ratings Changes

A number of research firms have weighed in on AGIO. Royal Bank Of Canada raised their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th. Bank of America increased their price target on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. JPMorgan Chase & Co. raised their price target on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Wednesday, June 24th. Finally, HC Wainwright upped their price objective on Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Agios Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $41.25.

Agios Pharmaceuticals Stock Performance

AGIO opened at $33.10 on Friday. The company’s 50-day simple moving average is $35.64 and its two-hundred day simple moving average is $31.84. The stock has a market capitalization of $1.98 billion, a P/E ratio of -4.72 and a beta of 0.60. Agios Pharmaceuticals, Inc. has a 52-week low of $22.24 and a 52-week high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The company had revenue of $44.75 million for the quarter, compared to analysts’ expectations of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. Research analysts forecast that Agios Pharmaceuticals, Inc. will post -5.82 EPS for the current fiscal year.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 30,000 shares of the business’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total transaction of $914,400.00. Following the completion of the sale, the insider directly owned 54,645 shares in the company, valued at approximately $1,665,579.60. The trade was a 35.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.40% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.